Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

298 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.
Yale JF, Aroda VR, Charbonnel B, Sinclair AJ, Trescoli C, Cahn A, Bigot G, Merino-Trigo A, Brulle-Wohlhueter C, Bolli GB, Ritzel R. Yale JF, et al. Among authors: charbonnel b. Diabetes Metab. 2020 Apr;46(2):110-118. doi: 10.1016/j.diabet.2018.10.002. Epub 2018 Oct 23. Diabetes Metab. 2020. PMID: 30366067 Free article. Clinical Trial.
Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
Owens DR, Bolli GB, Charbonnel B, Haak T, Landgraf W, Porcellati F, Traylor L, Kautzky-Willer A. Owens DR, et al. Among authors: charbonnel b. Diabetes Obes Metab. 2017 Nov;19(11):1546-1554. doi: 10.1111/dom.12966. Epub 2017 Jul 27. Diabetes Obes Metab. 2017. PMID: 28449412
Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes.
Bolli GB, Luzio S, Marzotti S, Porcellati F, Sert-Langeron C, Charbonnel B, Zair Y, Owens DR. Bolli GB, et al. Among authors: charbonnel b. Diabetes Obes Metab. 2011 Mar;13(3):251-7. doi: 10.1111/j.1463-1326.2010.01343.x. Diabetes Obes Metab. 2011. PMID: 21205115 Free PMC article. Clinical Trial.
A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.
Gastaldelli A, Balas B, Ratner R, Rosenstock J, Charbonnel B, Bolli GB, Boldrin M, Balena R. Gastaldelli A, et al. Among authors: charbonnel b. Diabetes Obes Metab. 2014 Feb;16(2):170-8. doi: 10.1111/dom.12192. Epub 2013 Aug 22. Diabetes Obes Metab. 2014. PMID: 23911196 Clinical Trial.
Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany.
Khunti K, Godec TR, Medina J, Garcia-Alvarez L, Hiller J, Gomes MB, Cid-Ruzafa J, Charbonnel B, Fenici P, Hammar N, Hashigami K, Kosiborod M, Nicolucci A, Shestakova MV, Ji L, Pocock S. Khunti K, et al. Among authors: charbonnel b. Diabetes Obes Metab. 2018 Feb;20(2):389-399. doi: 10.1111/dom.13083. Epub 2017 Sep 28. Diabetes Obes Metab. 2018. PMID: 28817227 Free PMC article.
298 results